A series of N-methyl-d-aspartate (NMDA) receptor-targeted MRI contrast agents has been developed, based on the known competitive NMDA antagonist, 3, 4-diamino-3-cyclobutene- 1, 2-dione. Their use as responsive MR imaging probes has been evaluated in vitro and two contrast agents showed 170–176% enhancements in